<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01615757</url>
  </required_header>
  <id_info>
    <org_study_id>AML HIDAC, AIIMS</org_study_id>
    <nct_id>NCT01615757</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Ara-c at 18 gm/m2 Versus 12 gm/m2 for 3 Cycles Each in AML Consolidation</brief_title>
  <acronym>Ara-c</acronym>
  <official_title>Comparison of Ara-c 12 gm/m2 vs 18 gm/m2 Per Cycle for 3 Cycles Each as Consolidation in AML ; An Open Label Randomized Non-inferiority Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>All India Institute of Medical Sciences, New Delhi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>All India Institute of Medical Sciences, New Delhi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be conducted in the Department of Medical Oncology and Department of&#xD;
      Haematology , AIIMS, Delhi. A total of 180 patients of Acute Myeloid Leukemia who are in&#xD;
      complete remission after induction chemotherapy will be enrolled into the study and will be&#xD;
      further randomized to the two study arms . ARM- A will receive Ara-c at 18 gm /m2 for 3&#xD;
      cycles and ARM -B will receive Ara-c at 12 gm/m2 for 3 cycles according to the study&#xD;
      protocol. Aim of the study will be to compare the efficacy of the two doses in terms of the&#xD;
      relapse free survival and overall survival as well as time to relapse and toxicity /treatment&#xD;
      related morbidity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives&#xD;
&#xD;
        -  To compare the efficacy of two different doses of Cytarabine during consolidation&#xD;
           therapy for newly diagnosed patients of Non APML - Acute Myeloid Leukemia who are in CR&#xD;
           post induction&#xD;
&#xD;
        -  To compare the toxicity of the two different Cytarabine doses&#xD;
&#xD;
      Primary end point&#xD;
&#xD;
        -  Relapse free survival at 1 yr from randomization&#xD;
&#xD;
        -  Relapse will be defined as &gt;5 % leukemic blasts in the marrow aspirate or new&#xD;
           extramedullary disease anytime after randomization&#xD;
&#xD;
      Secondary end points&#xD;
&#xD;
        -  Overall survival&#xD;
&#xD;
        -  Median time to relapse&#xD;
&#xD;
        -  Toxicity- Haematological and Non -Haematological&#xD;
&#xD;
      Inclusion criteria&#xD;
&#xD;
        -  Confirmation of Acute Myeloid Leukemia by morphologic, immunophenotypic analysis&#xD;
&#xD;
        -  Suitable for HIDAC as consolidation&#xD;
&#xD;
        -  AML with underlying MDS will be included&#xD;
&#xD;
      Exclusion criteria&#xD;
&#xD;
        -  Previous AML chemotherapy [Hydroxyurea - not an exclusion.]&#xD;
&#xD;
        -  CML-BC&#xD;
&#xD;
        -  Concurrent active malignancy&#xD;
&#xD;
        -  HIV infection, Uncontrolled Hepatitis B/C&#xD;
&#xD;
        -  Patients being considered for upfront PBSCT (before completion of CONSOLIDATION)&#xD;
&#xD;
        -  Serum Bilirubin &gt; 2&#xD;
&#xD;
        -  APML&#xD;
&#xD;
        -  Delayed recovery of blood counts /persistent active infection &gt; 45 days from start of&#xD;
           induction&#xD;
&#xD;
        -  Patients receiving reinduction with HIDAC&#xD;
&#xD;
        -  Therapy related AML Methodology&#xD;
&#xD;
        -  The period of enrollment will be from July 1, 2012 to September 30 ,2013&#xD;
&#xD;
        -  Baseline information will be recorded in a preformulated proforma designed for analysis&#xD;
           at a later date&#xD;
&#xD;
      Treatment&#xD;
&#xD;
        -  Standard 3 + 7 INDUCTION with Daunomycin and Cytarabine with DNR at 60- 90 mg/m2 as per&#xD;
           the PS and comorbidities/active infections at presentation&#xD;
&#xD;
        -  Bone marrow examination - D+ 28 of induction or earlier if needed . Patients not in CR -&#xD;
           reinduction regimen as per discretion of treating physician&#xD;
&#xD;
        -  Patients in complete morphological remission ( after 1 or 2 inductions) : will receive&#xD;
           consolidation with HIDAC and will be randomized into the two study arms after written&#xD;
           Informed Consent: Arm A and B with 90 patients in each arm Arm A will receive HIDAC at&#xD;
           18 gm/m2/cycle for 3 cycles , i.e. 3 gm/m2 BD , Day 1,3,5 Arm B will receive HIDAC at 12&#xD;
           gm/m2/cycle for 3 cycles , i.e. 2 gm/m2 BD , Day 1,3,5&#xD;
&#xD;
      sample size&#xD;
&#xD;
        -  Assuming a RFS of 60 % at 1 yr in each arm and keeping a non-inferiority margin of 20 %&#xD;
           , Alpha at 5 % ,75 patients are required in each arm on the basis of statistical&#xD;
           calculation.&#xD;
&#xD;
        -  15 patients added in each arm to account for losses&#xD;
&#xD;
        -  Total required in each arm = 90&#xD;
&#xD;
        -  ANC&gt; 1000 , Platelet count &gt; 1 lac required to start HIDAC&#xD;
&#xD;
        -  Detailed information of the course of all the chemotherapy cycles will be recorded&#xD;
           including-&#xD;
&#xD;
             1. toxicity&#xD;
&#xD;
             2. details of antimicrobials&#xD;
&#xD;
             3. supportive care ( including transfusions)&#xD;
&#xD;
             4. Use of growth factors&#xD;
&#xD;
        -  Cytogenetic analysis using standard technique of chromosomal banding&#xD;
&#xD;
        -  Molecular analysis for mutation of FLT3-ITD will be performed&#xD;
&#xD;
        -  Risk stratification will be done as per guidelines&#xD;
&#xD;
        -  Patients in both arms will be kept under close follow up and will be assessed with blood&#xD;
           counts /PS , 2 monthly / or earlier as clinically indicated&#xD;
&#xD;
      Statistical Analysis&#xD;
&#xD;
        -  Qualitative data will be analyzed using the Chi-square test&#xD;
&#xD;
        -  Quantitative data will be compared by using t-test /Mann Whitney test&#xD;
&#xD;
        -  Besides this survival analysis will be carried out.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse free survival at 1 yr of follow up</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity- Haematological and Non -Haematological</measure>
    <time_frame>at 1 yr</time_frame>
    <description>The following variables will be compared in the two arms to -&#xD;
-Nadir blood counts,Ara c related fever ,Allergic or skin reactions,Alopecia,Diarrhea ,Stomatitis,Bleeding ,Febrile neutropenia,Infection(fungal /bacterial/viral),Liver related event,ocular toxicity,Neurologic event,Peripheral neuropathy,Cerebral/Cerebellar toxicity,Transfusions,Time to recovery of platelets,Time to recovery of neutrophils,Duration of Hospital stay,Emergency visits,Deaths,Use of growth factors</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm B, Ara-c - 12 gm/m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B will receive HIDAC at 12 gm/m2/cycle for 3 cycles , i.e. 2 gm/m2 BD , Day 1,3,5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A. Ara-c 18 gm/m2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm A will receive HIDAC at 18 gm/m2/cycle for 3 cycles , i.e. 3 gm/m2 BD , Day 1,3,5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ara-c</intervention_name>
    <description>IV formulation, administered as a 2 hr infusion in 1 pint of normal saline, BD on D1,3,5 at 3 gm/m2 /dose</description>
    <arm_group_label>Arm A. Ara-c 18 gm/m2</arm_group_label>
    <other_name>Cytosar, Cytarabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ara-c</intervention_name>
    <description>IV formulation, administered as a 2 hr infusion in 1 pint of normal saline, BD on D1,3,5 at 2 gm/m2 /dose</description>
    <arm_group_label>Arm B, Ara-c - 12 gm/m2</arm_group_label>
    <other_name>Cytosar, Cytarabine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmation of Acute Myeloid Leukemia by morphologic, immunophenotypic analysis&#xD;
&#xD;
          -  Suitable for HIDAC as consolidation&#xD;
&#xD;
          -  AML with underlying MDS will be included&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous AML chemotherapy [Hydroxyurea - not an exclusion.]&#xD;
&#xD;
          -  CML-BC&#xD;
&#xD;
          -  Concurrent active malignancy&#xD;
&#xD;
          -  HIV infection, Uncontrolled Hepatitis B/C&#xD;
&#xD;
          -  Patients being considered for upfront PBSCT (before completion of CONSOLIDATION)&#xD;
&#xD;
          -  Serum Bilirubin &gt; 2&#xD;
&#xD;
          -  APML&#xD;
&#xD;
          -  Delayed recovery of blood counts /persistent active infection &gt; 45 days from start of&#xD;
             induction&#xD;
&#xD;
          -  Patients receiving reinduction with HIDAC&#xD;
&#xD;
          -  Therapy related AML&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prashant Mehta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AIIMS, Delhi, India</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vinod Raina, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AIIMS, Delhi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Prashant Mehta, MD</last_name>
    <phone>09013590847</phone>
    <email>prashantcipher@yahoo.co.in</email>
  </overall_contact>
  <location>
    <facility>
      <name>AIIMS</name>
      <address>
        <city>Delhi</city>
        <zip>110001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prashant Mehta, MD</last_name>
      <phone>09013590847</phone>
      <email>prashantcipher@yahoo.co.in</email>
    </contact>
    <investigator>
      <last_name>Prashant Mehta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>June 5, 2012</study_first_submitted>
  <study_first_submitted_qc>June 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2012</study_first_posted>
  <last_update_submitted>September 13, 2012</last_update_submitted>
  <last_update_submitted_qc>September 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>All India Institute of Medical Sciences, New Delhi</investigator_affiliation>
    <investigator_full_name>Prashant Mehta</investigator_full_name>
    <investigator_title>Senior Resident , Department of Medical Oncology</investigator_title>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Cytarabine dose</keyword>
  <keyword>Ara-c dose</keyword>
  <keyword>Consolidation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

